Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ciprofloxacin
Drug ID BADD_D00471
Description Ciprofloxacin is a second generation fluoroquinolone that has spawned many derivative antibiotics.[A178870] It is formulated for oral, intravenous, intratympanic, ophthalmic, and otic administration for a number of bacterial infections.[L6469,L6472,L6475,L6478,L6481,L6484,L6487,L6490,L6493] The first ciprofloxacin containing product was FDA approved on 22 October 1987.[L6463]
Indications and Usage Ciprofloxacin is only indicated in infections caused by susceptible bacteria.[L6469,L6472,L6475,L6478,L6481,L6484,L6487,L6490,L6493] Ciprofloxacin immediate release tablets, oral suspensions, and intravenous injections are indicated for the treatment of skin and skin structure infections, bone and joint infections, complicated intra-abdominal infections, nosocomial pneumonia, febrile neutropenia, adults who have inhaled anthrax, plague, chronic bacterial prostatitis, lower respiratory tract infections including acute exacerbations of chronic bronchitis, urinary tract infections, complicated urinary tract infections in pediatrics, complicated pyelonephritis in pediatrics, and acute sinusitis.[L6481,L6478] A ciprofloxacin otic solution and otic suspension with hydrocortisone are indicated for acute otitis externa.[L6469,L6484] Ciprofloxacin suspension with dexamethasone is indicated for acute otitis media in pediatric patients with tympanostomy tubes or acute otitis externa.[L6490] A ciprofloxacin intratympanic injection is indicated for pediatric patients with bilateral otitis media with effusion who are having tympanostomy tubes placed or pediatric patients 6 months or older with acute otitis externa.[L6493] A ciprofloxacin eye drop is indicated for bacterial corneal ulcers and conjunctivitis.[L6472] A ciprofloxacin eye ointment is indicated for bacterial conjunctivitis.[L6475] A ciprofloxacin extended release tablet is indicated for uncomplicated urinary tract infections, complicated urinary tract infections, and acute uncomplicated pyelonephritis.[L6487]
Marketing Status approved; investigational
ATC Code J01MA02; S01AE03; S02AA15; S03AA07
DrugBank ID DB00537
KEGG ID D00186
MeSH ID D002939
PubChem ID 2764
TTD Drug ID D0O1WX
NDC Product Code 72789-118; 82982-025; 42708-146; 67296-1848; 0409-2300; 70518-3063; 70985-008; 71610-081; 76420-214; 12527-0537; 16252-516; 52286-0014; 16571-412; 50090-5483; 55111-126; 60429-042; 61919-795; 62135-392; 68071-1893; 68071-2913; 69315-308; 71335-2097; 72189-300; 0615-8367; 72789-193; 53069-0680; 36000-297; 0143-9929; 45865-471; 50090-4220; 55111-125; 62135-393; 63187-001; 66992-450; 67296-1269; 68071-2525; 68788-7905; 68788-9012; 70985-011; 71335-1867; 71335-2054; 63187-017; 63629-7786; 66267-919; 68788-7500; 71205-749; 71335-1640; 0904-7083; 16252-514; 36000-009; 0143-9927; 55154-3368; 55700-737; 58657-676; 63629-1724; 63629-5154; 67296-1097; 67296-1389; 67296-1479; 68071-3013; 68788-9006; 70518-2390; 72789-124; 0904-7243; 42708-088; 45865-530; 53002-2642; 53002-2790; 55111-128; 58657-675; 63629-1326; 67296-1575; 0409-3300; 0409-4777; 70518-0693; 70934-316; 72789-125; 16571-413; 45865-772; 53002-2640; 63629-3868; 67296-0237; 67296-1318; 68788-8200; 72189-242; 80425-0164; 55111-015; 25021-192; 35356-733; 0143-9928; 50090-4217; 61919-371; 63187-990; 68071-4201; 0904-6378; 58032-0127; 16571-411; 25021-114; 36000-008; 43063-547; 43063-767; 51655-086; 54348-662; 54348-663; 55111-127; 60760-815; 61919-361; 63187-142; 63629-7950; 68788-9280; 70518-2837; 70985-012; 71335-1393; 16252-515; 42195-550; 43063-410; 43063-869; 60760-676; 68071-2267; 68071-2269; 68788-7864; 68788-9024; 70518-3417; 71205-300; 71335-0070; 71335-0408; 72189-304; 72189-323; 72789-108; 12527-0540; 36000-298; 42708-002; 45865-994; 50090-5621; 50419-773; 50419-777; 51655-118; 51655-490; 53002-2791
UNII 5E8K9I0O4U
Synonyms Ciprofloxacin | Ciprofloxacin Hydrochloride Anhydrous | Anhydrous, Ciprofloxacin Hydrochloride | Hydrochloride Anhydrous, Ciprofloxacin | Cipro | Ciprofloxacin Hydrochloride | Hydrochloride, Ciprofloxacin | Ciprofloxacin Monohydrochloride Monohydrate | Monohydrate, Ciprofloxacin Monohydrochloride | Monohydrochloride Monohydrate, Ciprofloxacin | Bay-09867 | Bay 09867 | Bay09867 | Ciprinol
Chemical Information
Molecular Formula C17H18FN3O3
CAS Registry Number 85721-33-1
SMILES C1CC1N2C=C(C(=O)C3=CC(=C(C=C32)N4CCNCC4)F)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Prothrombin time prolonged13.01.02.012--Not Available
Prothrombin time shortened13.01.02.013--Not Available
Prurigo23.03.04.017--Not Available
Pruritus23.03.12.0010.000043%
Pruritus genital23.03.12.008; 21.10.01.002--Not Available
Pseudomembranous colitis11.02.02.002; 07.19.01.003--Not Available
Pulmonary embolism24.01.06.001; 22.06.02.001--Not Available
Pulmonary haemorrhage22.12.01.009; 24.07.01.016--
Pulmonary oedema22.01.03.003; 02.05.02.003--
Punctate keratitis06.04.02.003--Not Available
Purpura01.01.04.003; 24.07.06.005; 23.06.01.004--
Pyrexia08.05.02.0030.000054%
Radial nerve palsy17.09.02.004--Not Available
Rash23.03.13.0010.000123%Not Available
Rash macular23.03.13.003--Not Available
Rash maculo-papular23.03.13.004--
Rash papular23.03.13.017--Not Available
Rash pruritic23.03.13.030--Not Available
Rash pustular23.03.10.003; 11.01.12.002--
Renal disorder20.01.02.002--Not Available
Renal failure20.01.03.005--Not Available
Renal pain20.02.03.003--Not Available
Renal tubular necrosis20.01.07.0030.000058%Not Available
Renal vasculitis20.01.07.007; 10.02.02.013; 24.12.04.021--Not Available
Repetitive strain injury12.01.07.005--Not Available
Respiratory acidosis22.02.02.004; 14.01.04.002--Not Available
Respiratory arrest22.02.01.009--Not Available
Respiratory distress22.02.01.012--Not Available
Restlessness19.11.02.002; 17.02.05.021--
Retinal detachment12.01.04.004; 06.09.03.003--
The 14th Page    First    Pre   14 15 16 17 18    Next   Last    Total 23 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene